Avances en el tratamiento farmacológico del tabaquismo: vareniclina, una nueva molécula disponible / Pharmacological breakthrough for the treatment of tobacco smoking: vareniclin; a new disposable molecule
Med. mil
; 62(4): 213-214, oct.-dic. 2006.
Article
in Spanish
| IBECS
| ID: ibc-60336
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
La vareniclina, agonista parcial de los receptores nicotínicos, se añade en el momento actual al arsenal terapéutico de primera línea utilizable para ayudar a dejar de fumar. Se trata de un fármaco bien tolerado, seguro y de eficacia probada con escasos efectos secundarios (AU)
ABSTRACT
Vareniclin, partially agonist of the nicotinic receptors, is added to the therapies collection of drugs for the front line in the current days, useful when the stop smoking aid is sought. It is a well tolerated drug, sure and with efficiency well proved, just with few secondary effects (AU)
Search on Google
Collection:
National databases
/
Spain
Health context:
SDG3 - Target 3A Strengthen the implementation of the WHO Framework Convention on Tobacco Control
Health problem:
Protection from Exposure
/
Tobacco Dependence and Cessation
Database:
IBECS
Main subject:
Smoking
/
Nicotinic Agonists
Limits:
Humans
Language:
Spanish
Journal:
Med. mil
Year:
2006
Document type:
Article
Institution/Affiliation country:
Hospital Central de la Defensa Gómez Ulla/España
